China-based Sunflower Pharmaceutical Group Co., Ltd. (SHE: 002737) is poised to establish a joint laboratory with the Peking University Health Science Center (PKUHSC), focusing on research and development of bacterial enzymes and innovative drugs. This strategic collaboration aims to advance scientific research and pharmaceutical innovation in the field.
Investment in Research and Development
Sunflower Pharma is committed to investing no less than RMB 10 million (USD 1.38 million) in the joint laboratory, ensuring the smooth operation and scientific research activities. This significant investment underscores the company’s dedication to driving forward advancements in pharmaceuticals and healthcare solutions.
Focus on Bacterial Enzymes and Innovative Drugs
The joint laboratory will concentrate on bacterial enzymes, which are crucial in various biological processes and have potential applications in drug development. By combining the expertise of Sunflower Pharmaceutical Group with the academic resources of PKUHSC, the partnership is well-positioned to yield groundbreaking discoveries and contribute to the development of innovative drugs.-Fineline Info & Tech
